Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Interest Income

Income earned on cash, deposits, and investments held by the company.

Bioventus Inc.NASDAQ: BVS

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.

Context

  • Interest income amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Income vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 interest income of $0 is the 6th highest of the 9 companies compared; the peer median is $1.01M.
  • Interest income amounts to 0.0% of revenue for BVS, versus a peer median of 0.3%.
BVS Competitors Peer median
Interest Income for BVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$28.07M +16.9%+26.1%0.5%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$15.08M -10.2%+15.7%0.9%
MDXGMiMedx Group, Inc.LTM Mar 2026$3.81M -9.2%—1.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$1.7M +76.9%—0.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$313K —+44.7%0.3%
BVSBioventus Inc.LTM Mar 2026$0 ——0.0%
OFIXOrthofix Medical Inc.LTM Mar 2026$0 ——0.0%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
TELATELA Bio, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding BVS) $1.01M-9.2%+26.1%0.3%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue430.9M512.12M512.35M573.28M568.09M
Cost of Revenue128.19M181.04M184.15M185.05M185.66M
Gross Profit302.71M331.08M328.19M388.23M382.43M
Gross Margin70.3%64.6%64.1%67.7%67.3%
Research & Development19.04M23.85M13.45M13.64M12.11M
Selling, General & Admin254.25M332.13M303.88M327.09M311.77M
Operating Expenses290.65M498.31M409.92M400.21M323.88M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
EBITDA45.48M(121.61M)(23.07M)39.22M99.21M
EBITDA Margin10.6%-23.7%-4.5%6.8%17.5%
Operating Income12.06M(167.23M)(81.73M)(11.98M)58.55M
Operating Margin2.8%-32.7%-16.0%-2.1%10.3%
Interest Income00000
Interest Expense1.11M12.02M40.68M38.79M26.49M
Other Income / Expenses(2.57M)(21.79M)(39.39M)(37.15M)(32.84M)
Income Before Tax9.49M(189.03M)(121.11M)(49.13M)25.71M
Pre-Tax Margin2.2%-36.9%-23.6%-8.6%4.5%
Income Tax Expense(1.97M)(44.37M)85K(5.29M)(1.57M)
Net Income19.38M(158.7M)(156.23M)(33.54M)22.73M
Net Margin4.5%-31.0%-30.5%-5.9%4.0%
EPS (Basic)(0.15)(2.59)(2.49)(0.52)0.34
EPS (Diluted)(0.15)(2.59)(2.49)(0.52)0.33
Weighted Avg Shares45.47M61.39M62.65M65.36M66.62M
Weighted Avg Shares (Diluted)45.47M61.39M62.65M65.36M68.91M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.